Transcoronary Concentration Gradients of Circulating MicroRNAs

Abstract

Background-Circulating levels of microRNA (miR) have been proposed as biomarkers for cardiovascular disease. To identify the heart as a potential source for miRs released into the circulation, we measured concentration gradients across the coronary circulation for muscle-enriched (miR-133a, miR-499, miR-208a), vascular (miR-126, miR-92a), leukocyterelated (miR-155), and platelet-enriched (miR-223) miRs. Methods and Results-Circulating miRs were measured by TaqMan polymerase chain reaction in EDTA-plasma simultaneously obtained from the aorta and the coronary venous sinus in patients without coronary artery disease (nϭ7), with stable coronary artery disease (nϭ31), and with troponin-positive acute coronary syndromes (nϭ19). Circulating levels of the muscle-enriched miR-499 (Ͼ20-fold; PϽ0.01), miR-133a (11-fold; PϽ0.01), and miR-208a (5-fold; PϽ0.01) were significantly elevated in the aorta of troponin-positive acute coronary syndrome patients compared with patients with coronary artery disease. Importantly, there was a significant increase in circulating levels of miR-499 and miR-133a across the coronary circulation in troponin-positive acute coronary syndrome patients, suggestive of a release into the coronary circulation during myocardial injury. Indeed, miR-499 concentration gradients were significantly correlated with the extent of myocardial damage as measured by high-sensitivity troponin T (rϭ0.70, PϽ0.01). In contrast, circulating levels of miR-126 (Pϭ0.16) decreased during transcoronary passage in patients with evidence of myocardial injury, suggesting consumption during transcoronary passage. Conclusions-Muscle-enriched miR-499 and miR-133a are released from the heart into the coronary circulation on myocardial injury, whereas the vascular miR-126 is consumed during transcoronary passage. The differential regulation of circulating miRs during the transcoronary passage might provide important insights to exploit their role as cardiac biomarkers. Clinical Trial Registration-URL: http://www.germanctr.de. Unique identifier:

Circulating Microparticles Decrease After Cardiac Stress in Patients With Significant Coronary Artery Stenosis

“…This concept is in line with a study from da Rosa et al, who showed that circulating miR-126 is consumed most probably from the endothelium during the passage of the culprit lesion in patients with an acute coronary syndrome. 32 Considering that miR-126 is highly expressed and mainly transported within EMPs, 15 these findings support the concept that the ischemic endothelium increases its abilities to take up EMPs to prevent cell damage and death.…”

Epidemiology: Disease Associations and Modulators of HDL-Related Biomarkers

“…miRNAs are ideal biomarkers since they are stable and their sequences can be easily amplified. Alterations in circulating miRNA profiles have been associated with cardiovascular risk factors such as hypertension, diabetes, and dyslipidemias as well as with cardiovascular diseases such as coronary heart disease, myocardial infarction, and heart failure de Rosa et al 2011). However, this association has not been found in all studies (Wagner et al 2013).…”

Endothelial MicroRNA Tells Smooth Muscle Cells to Proliferate

“…The miR-126 levels in the plasma have been positively and negatively associated with various cardiovascular clinical entities. [13][14][15] Even though the reported studies did not distinguish between miR-126 in protein complexes and vesicles, it was found that circulating miR-126 decreases during transcoronary passage, 16 which could indicate an uptake of miR-126 by, for example, smooth muscle cells, thereby aggravating atherosclerosis. However, whether protein-bound miR-126 is also released into the circulation or whether it is just secreted to the basal side of endothelial cells into the intima is not known but highly likely, because miR-126 is found in protein complexes and vesicles in plasma.…”